All News

Jo1.gottrons.jpg

ProDERM Study: IVIG in Dermatomyositis

d Jack Cush, MD

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article
lupus.nephritis.immunofluorescence.jpg

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

d Jack Cush, MD

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.

Read Article
Xeljanz4.jpg

Delays in Diagnosis of Axial Spondyloarthritis

d Jack Cush, MD

The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular manifes

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Shortage During COVID-19

d Jack Cush, MD

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.

Read Article
Adipose fat cells

Adipose Transplants as a New Regulator of Osteoarthritis

d Jack Cush, MD

A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.

Read Article
ACR Convergence 2020 Fireside Chats- top presentations in nr-axSpA, AS, axial PsA and Still’s disease. Sponsored by Novartis Medical Affairs Unable to attend the key sessions at #ACR20? Listen to the experts as they weigh in on the top abstracts. https://t.co/oGwmEXNaur https://t.co/S23cZw4Li1

Links:

Dr. John Cush RheumNow ( View Tweet)
Chinese SLE CSTAR study of 4792 SLE patients, of whom 374 (7.8%) had scarring alopecia. Risk factors for scarring alopecia included mucocutaneous lesions (OR 2.1) high SLICC/ACR-DI (OR 1.4), & positive Sm (OR 1.4), but less seen w/ renal CV involvement https://t.co/Y466WK3shS

Links:

Dr. John Cush RheumNow ( View Tweet)

Survey of 428 Rheums in Brazil finds they are prone to promote physical activity; but less than 1/4 had training, 14% dont assess phys activity routinely, & half dont know minimum recommendations. Major gaps in knowledge about physical activity recs exist https://t.co/7WwuR0bqpJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Telemedicine study on accuracy of Pt reported swelling predicting inflamm arthritis. 1637 pts w/ 13 wks of Sxs. 76% pts reported swelling, but only found by 41% of Rheums. Pt reporting sensitivity was was 87%, but specificity only 31%; PPV=46%, NPV=77% https://t.co/oV3p06BHRj

Links:

Dr. John Cush RheumNow ( View Tweet)

New year, new QD Clinic- Clinic Emergencies. https://t.co/xyaVP8ZkmB https://t.co/QXTvp2mttV

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 52 pts w/ pericardial dz in GCA (44) & PMR (8) finds only 46% were >70 yrs. Manifest as pericardial effusion (85%), was initial Sx in 37%. 69% were symptomatic & classic cranial Sxs present in only 40%. Tamponade more likely w/ PMR https://t.co/B5IxBT9OO7

Links:

Dr. John Cush RheumNow ( View Tweet)

Adipose Transplants as a New Regulator of Osteoarthritis--A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself. Read more: https://t.co/0VpR4VPmBX https://t.co/jSALMKXrhB

Links:

Dr. John Cush RheumNow ( View Tweet)
147 Obese patients (25 w/ gout, 55 w/ hyperuricemia) had bariatric surgery. 1 yr after sugery, pts lost mean 31 kg & decreased uric acid from 419 to 308 µmol 1–7 days postop and 328 @12 mos (P < 0.001). 40% of gout pts were at/below target. https://t.co/9e8zpWKHay

Links:

Dr. John Cush RheumNow ( View Tweet)

Download your RheumaKnowledgy Card https://t.co/L7O0UFjEBV https://t.co/iFtVKERnjC

Links:

Dr. John Cush RheumNow ( View Tweet)
Corticosteroid Use Hikes CV Risks in Rheumatic Patients--It is long known that high-dose steroids may increase the risk of cardiovascular disease (CVD), heart disease, stroke, or other vascular outcomes, but it is unknown what the risk is at lower doses. https://t.co/gkTLP3ceVD https://t.co/HMpvpham1q

Links:

Dr. John Cush RheumNow ( View Tweet)
Medicare's 'Most Favored Nation' Drug-Pricing Rule in Limbo--The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office. https://t.co/3NnvyRiVDo https://t.co/gLSFERaNku

Links:

Dr. John Cush RheumNow ( View Tweet)
SOBI announced Kineret is now FDA approved to treat DIRA (defic of IL-1 receptor antagonist), an ultra-rare, autoinflammatory Dz caused by a genetic mutation in the IL1RN gene,. Pts have life-threatening systemic inflammation with skin and bone involvement https://t.co/iccvWYJva9

Links:

Dr. John Cush RheumNow ( View Tweet)

National Psoriasis Foundation Task Force updated their COVID-19 guidance statements. Including Guidance 4.6, stating PsA pts who receive a mRNA-COVID vaccine should continue their biologic or oral therapies as they manag of their psoriatic disease https://t.co/byujtDET33

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study of 171 GCA patients found that 32% had aoritis (by Sxs or AI murmur); hese pts were 6 fold more likely to have subsequent Aortic complications (aortic aneurysms or dissection) https://t.co/zRVzmnU7JH

Links:

Dr. John Cush RheumNow ( View Tweet)

After your 2 doses of COVID vaccine, YES you need to continue to wear a mask, cont. hand washing & social distancing - so as to continue to protect yourself and others. While vaccinated you can still become infected and spread infection. https://t.co/TkcSNx0hF1

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×